FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy
Executive Summary
FDA's warning about 19 deaths related to excessive, off-label dosing for Ocaliva in primary biliary cholangitis spurs fears doctors will curtail prescribing and, worse, that the larger upcoming NASH market opportunity may be affected.
You may also be interested in...
Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch
Intercept announced that the US FDA has set April 22 as date for an advisory committee review of OCA in NASH, meaning March 26 action date could be pushed back as much as three months.
Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On
Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy.
US FDA References Off-Label Use In Otherwise Bland Labeling Draft Guidance
Product labels can be required to have warnings related to commonly prescribed unapproved uses with significant safety risks.